Table 1.
Patients’ demographic and clinical characteristics.
| Patients’ demographic and clinical characteristics | N=56 |
|---|---|
| Male, (%) | 32 (57) |
| Age at diagnosis, median (IQR), y | 26 (22–41) |
| Age at infliximab initiation, median (IQR), y | 37 (28–50) |
| Disease duration: median (IQR), years | 4 (1–11) |
| Pancolitisa, (%) | 29 (52) |
| Smoking ever, (%) | 11 (20) |
| Prior infliximab optimization at first TDM, (%) | 35 (62) |
| Concomitant IMMb at first TDM, (%) | 18 (32) |
| BMI at first TDM, median (IQR), Kg/m2, (n=47) | 24.6 (23.3–28.1) |
| CRP >5 mg/L at first TDM, (%) | 3/10 (30) |
| Albumin at first TDM, median (IQR), g/dL, (n=17) | 3.9 (3.8–4.3) |
| Infliximab TC at first TDM, median (IQR), μg/mL | 6.9 (2.3–11.5) |
| ATI at first TDM, (%) | 8/55 (15) |
| Type of assay at first TDM: HMSA, (%) | 41 (73.2) |
a
according to Montreal classification for disease extension (E3);
b
thiopurines
BMI: body mass index; CRP: C-reactive protein; IMM: immunomodulators; IQR: interquartile range; TC: trough concentration; TDM: therapeutic drug monitoring; ATI: antibodies to infliximab; y: years; HMSA: homogeneous mobility shift assay.